When researchers pooled data from six major semaglutide weight-loss trials and zeroed in on participants aged 65 and older, the results were striking: significant weight loss paired with broad improvements in blood pressure, cholesterol, and blood sugar control compared with placebo. The findings, presented as conference data at the European Congress on Obesity (ECO) in May 2026, offer the most comprehensive look yet at how the blockbuster drug performs in older adults, a population that was underrepresented in each individual trial. No specific abstract number or lead author has been publicly identified for the presentation, and the data have not yet undergone peer review.
The analysis did not stand alone. Cardiovascular outcomes data from the landmark SELECT trial, published in the New England Journal of Medicine, had already shown that semaglutide 2.4 mg reduced heart attacks, strokes, and cardiovascular deaths in people with obesity or overweight and established heart disease but without diabetes. Taken together, the evidence is building a case that Ozempic’s active ingredient delivers real cardiometabolic benefits well past age 65, even as important questions about muscle loss and physical function remain unanswered.
What the pooled STEP data actually showed
The ECO 2026 presentation drew on STEP trials 1, 3, 4, 5, 8, and 9, combining their older participants into a single analysis with enough statistical power to detect patterns that no individual trial could confirm on its own. Adults 65 and older in the semaglutide groups showed improvements across several cardiometabolic markers: systolic and diastolic blood pressure, LDL cholesterol, triglycerides, and HbA1c, the standard measure of long-term blood sugar control.
The pooling matters because older adults made up a relatively small slice of each STEP trial’s enrollment. Analyzing them collectively gives clinicians more confidence that the benefits seen in younger participants extend to people in their late 60s, 70s, and beyond. That said, the precise magnitude of weight loss and the exact numerical changes in each marker for this subgroup have not yet appeared in a peer-reviewed publication. Conference presentations, while valuable, undergo less rigorous scrutiny than journal articles, and clinicians will want to see the full data before drawing firm conclusions about how the effect size in older adults compares with that in younger participants.
SELECT: hard cardiovascular outcomes, not just lab numbers
The SELECT trial stands apart from the STEP program because it was designed to answer a different and arguably more consequential question: does semaglutide actually prevent heart attacks and strokes, or does it just improve the numbers that predict them?
The answer, based on more than 17,600 participants followed for a mean of roughly 40 months, was that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared with placebo. The trial was event-driven, meaning it continued until a pre-specified number of cardiovascular events had occurred rather than stopping at a fixed calendar date. That design is considered the gold standard in cardiology research because it focuses on outcomes patients and doctors care about most: survival and freedom from catastrophic cardiac events.
For older adults, who carry the highest absolute cardiovascular risk, this type of evidence is especially persuasive. A 20% relative reduction in events translates into a larger absolute benefit when the baseline event rate is high, which it typically is in people over 65 with established heart disease and excess weight.
A secondary analysis published in Nature Medicine extended the observation window from SELECT and found that weight loss with semaglutide was largely maintained over several years. Because it was a secondary analysis rather than a primary trial endpoint, the findings carry somewhat less evidentiary weight, though they remain informative. While the analysis was not restricted to older adults, a substantial portion of SELECT participants were over 65, offering some reassurance that age does not erase the durability of the drug’s effects.
Kidney markers improved too
A peer-reviewed analysis derived from SELECT data evaluated renal outcomes including estimated glomerular filtration rate (eGFR) and albuminuria, both key indicators of kidney health. Semaglutide was associated with favorable changes in these markers compared with placebo.
This matters disproportionately for older adults. Chronic kidney disease becomes increasingly common with age, and many patients over 65 already have mildly or moderately reduced kidney function. A treatment that improves cardiovascular risk, promotes weight loss, and shows kidney-protective signals addresses several of the conditions that cluster together in aging bodies. Earlier exploratory analyses from STEP 1 and STEP 4 had already documented improvements in waist circumference, fasting glucose, fasting insulin, and inflammatory markers like C-reactive protein, reinforcing the idea that semaglutide’s benefits extend across multiple organ systems rather than operating in isolation.
The muscle and function gap
For all the encouraging metabolic data, the most pressing concern for geriatric medicine remains largely unaddressed: what happens to muscle mass and physical function when older adults lose significant weight on semaglutide?
Weight loss in people over 65 almost always includes some loss of lean muscle tissue. When that loss is substantial, it can increase fall risk, reduce mobility, and accelerate the slide toward frailty. None of the cited STEP or SELECT publications report baseline lean-mass measurements, grip strength, or gait speed specifically for participants over 65. There are no published falls data, no frailty-index tracking, and no post-trial follow-up on physical performance for older semaglutide users in either program.
The European Association for the Study of Obesity (EASO) has flagged this concern directly. Its position statement on obesity management in older adults highlights the risk of sarcopenic obesity, a condition in which excess fat coexists with dangerously low muscle mass, and calls for multimodal management that preserves functional status. The guidance makes clear that pharmacotherapy alone is not sufficient for this age group. Resistance exercise, adequate protein intake (often 1.0 to 1.2 grams per kilogram of body weight daily), and regular monitoring of physical performance should accompany any weight-loss medication.
This is not a theoretical worry. Clinicians who treat older adults with GLP-1 receptor agonists report that gastrointestinal side effects, particularly nausea and reduced appetite, can make it harder for patients to consume enough protein to protect muscle. The STEP trials used standard dosing across age groups, which simplifies efficacy comparisons but leaves open questions about whether slower titration schedules or lower maintenance doses might reduce side effects and improve tolerability in frailer patients. In practice, many prescribers already adjust the pace of dose escalation for older adults, but that real-world approach has not been formally studied.
Generalizing trial results to real-world older adults
Clinical trials enroll carefully screened participants who receive regular follow-up, structured lifestyle counseling, and close medical monitoring. Many older adults in routine practice look quite different: they take more medications, manage more chronic conditions, and often have limited access to dietitians or supervised exercise programs. Some live in long-term care facilities. Some have cognitive impairment that complicates medication adherence.
That gap between trial populations and everyday patients is a standard limitation in pharmaceutical research, but it is especially relevant here. The over-65 subgroup in the STEP and SELECT trials was healthy enough to meet enrollment criteria, which typically excluded people with severe kidney disease, uncontrolled heart failure, or significant frailty. Clinicians cannot assume that the benefits observed in these relatively robust older participants will translate identically to the broader geriatric population.
Cost and access add another layer of complexity. GLP-1 receptor agonists remain expensive, and Medicare coverage for obesity treatment has historically been limited. While policy changes are evolving, many older adults on fixed incomes face significant out-of-pocket costs that can affect whether they start or continue therapy. That practical reality shapes prescribing decisions in ways that trial data alone cannot capture.
Semaglutide’s cardiometabolic reach into older age as of June 2026
The overall picture is internally consistent and increasingly persuasive. Across the STEP and SELECT programs, semaglutide produces substantial weight loss, improves a broad range of cardiometabolic markers, lowers the risk of major cardiovascular events, and shows favorable kidney signals. The pooled ECO 2026 analysis adds confidence that adults over 65 share in these benefits, at least in terms of weight reduction and laboratory outcomes.
What the data do not yet provide are the details that matter most to geriatric care: how much muscle is lost along the way, how physical function changes over months and years of treatment, and whether the balance of benefit and risk shifts meaningfully in the oldest and frailest patients. Those answers will require dedicated trials or large-scale post-marketing studies with functional endpoints built into the design.
For now, the evidence supports offering semaglutide to carefully selected older adults with obesity or overweight and elevated cardiovascular risk, paired with transparent conversations about what is known and what is not. Strength-preserving strategies, including resistance training and protein-rich nutrition, should be treated as non-negotiable companions to the prescription. As more age-specific data emerge, the clinical picture for adults over 65 will sharpen. But the current record already signals something that was far from certain just a few years ago: semaglutide’s cardiometabolic reach extends meaningfully into older age, and the drug appears to do more than just shrink waistlines in this population.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
